Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Piper Sandler has reiterated an Overweight rating and $150.00 price target on Abbott Labs (NYSE:ABT), currently trading near its 52-week high at $131.60, ahead of the company’s second-quarter earnings report expected on July 17. According to InvestingPro, Abbott maintains a "GREAT" financial health score and commands a market capitalization of $228.81 billion.
The firm anticipates Abbott will deliver results that meet or exceed expectations for Q2, with the medical technology segment projected to lead performance with potential upside to their estimated 10.9% growth excluding foreign exchange impacts. Diabetes and structural heart divisions are expected to be the primary growth drivers within the medtech business. InvestingPro data shows Abbott has maintained dividend payments for 55 consecutive years, demonstrating remarkable financial stability.
Piper Sandler identified several key topics to monitor during the upcoming earnings call, including the timing and commercial expectations for Abbott’s dual analyte (glucose + ketone) product, potential impacts from proposed competitive bidding in diabetes, feedback on the European Volt launch, and U.S. timing expectations.
The firm also expressed interest in updates regarding ongoing infant formula litigation, which is currently in the multi-district litigation process. Broader discussion may begin shifting toward Abbott’s fiscal year 2026 outlook, where Piper Sandler sees potential for accelerated top-line growth.
Last month, Piper Sandler named Abbott its favorite large-cap stock heading into the second half of 2025 and 2026, maintaining that Abbott represents the best opportunity for growth-at-reasonable-price exposure within large-cap medical technology companies.
In other recent news, Abbott Laboratories has been the focus of several significant developments. TD Cowen reiterated its Buy rating on Abbott Labs with a price target of $145, anticipating the company will meet or exceed Wall Street’s expectations for the upcoming second-quarter earnings report. Oppenheimer also maintained an Outperform rating, setting a $140 price target, citing optimism about Abbott’s Volt system and upcoming glucose-ketone monitoring technology. Piper Sandler highlighted Abbott as a key beneficiary in the growing continuous glucose monitoring market, noting strong adoption among basal insulin patients.
Additionally, Abbott announced a quarterly dividend of 59 cents per share, marking its 406th consecutive quarterly dividend since 1924 and maintaining its status in the S&P 500 Dividend Aristocrats Index. Oppenheimer further noted potential catalysts for Abbott in the second half of 2025, such as the potential Volt PMA approval and integration of its dual sensor system with Tandem Diabetes Care (NASDAQ:TNDM)’s insulin pump. The Centers for Medicare & Medicaid Services’ final decision on transcatheter edge-to-edge repair for the tricuspid valve was also favorable for Abbott, as noted by Oppenheimer. These developments collectively highlight Abbott’s ongoing strategic advancements and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.